A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

NCT01461928 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

692

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Chemotherapy (Induction Period)
DRUG: Rituximab

Sponsor

Hoffmann-La Roche